104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease:a phase III open-label extension study (ATB200-07)

MLA

Schoser, Benedikt, et al. “104-Week Efficacy and Safety of Cipaglucosidase Alfa plus Miglustat in Adults with Late-Onset Pompe Disease:A Phase III Open-Label Extension Study (ATB200-07).” Schoser , B , Kishnani , P S , Bratkovic , D , Byrne , B J , Claeys , K G , Díaz-Manera , J , Laforêt , P , Roberts , M , Toscano , A , van Der Ploeg , A T , Castelli , J , Goldman , M , Holdbrook , F , Sitaraman Das , S , Wasfi , Y & Mozaffar , T 2024 , ’ 104-Week Efficacy and Safety of Cipaglucosidase Alfa plus Miglustat in Adults with Late-Onset Pompe Disease : A Phase III Open-Label Extension Study (ATB200-07) ’ , Journal of Neurology , Vol. 271 , No. 5 , Pp. 2810-2823 , 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1430692571&authtype=sso&custid=ns315887.

APA

Schoser, B., Kishnani, P. S., Bratkovic, D., Byrne, B. J., Claeys, K. G., Díaz-Manera, J., Laforêt, P., Roberts, M., Toscano, A., van der Ploeg, A. T., Castelli, J., Goldman, M., Holdbrook, F., Sitaraman Das, S., Wasfi, Y., & Mozaffar, T. (2024). 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease:a phase III open-label extension study (ATB200-07). Schoser , B , Kishnani , P S , Bratkovic , D , Byrne , B J , Claeys , K G , Díaz-Manera , J , Laforêt , P , Roberts , M , Toscano , A , van Der Ploeg , A T , Castelli , J , Goldman , M , Holdbrook , F , Sitaraman Das , S , Wasfi , Y & Mozaffar , T 2024 , ’ 104-Week Efficacy and Safety of Cipaglucosidase Alfa plus Miglustat in Adults with Late-Onset Pompe Disease : A Phase III Open-Label Extension Study (ATB200-07) ’ , Journal of Neurology , Vol. 271 , No. 5 , Pp. 2810-2823 .

Chicago

Schoser, Benedikt, Priya S. Kishnani, Drago Bratkovic, Barry J. Byrne, Kristl G. Claeys, Jordi Díaz-Manera, Pascal Laforêt, et al. 2024. “104-Week Efficacy and Safety of Cipaglucosidase Alfa plus Miglustat in Adults with Late-Onset Pompe Disease:A Phase III Open-Label Extension Study (ATB200-07).” Schoser , B , Kishnani , P S , Bratkovic , D , Byrne , B J , Claeys , K G , Díaz-Manera , J , Laforêt , P , Roberts , M , Toscano , A , van Der Ploeg , A T , Castelli , J , Goldman , M , Holdbrook , F , Sitaraman Das , S , Wasfi , Y & Mozaffar , T 2024 , ’ 104-Week Efficacy and Safety of Cipaglucosidase Alfa plus Miglustat in Adults with Late-Onset Pompe Disease : A Phase III Open-Label Extension Study (ATB200-07) ’ , Journal of Neurology , Vol. 271 , No. 5 , Pp. 2810-2823 . http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1430692571&authtype=sso&custid=ns315887.